Kite Acquires Interius BioTherapeutics for $350 Million

California, August 27, 2025

News Summary

Kite, a California-based biopharmaceutical company and subsidiary of Gilead Sciences, has announced its acquisition of Interius BioTherapeutics for $350 million. This strategic move aims to enhance Kite’s capabilities in developing next-generation in vivo therapies, particularly those involving CAR T-cells generated directly within patients’ bodies. Following the acquisition, Interius’s operations will merge with Kite’s research team, and a new center of excellence for in vivo therapy development will be established in Philadelphia. The deal is expected to impact Gilead’s earnings with a forecasted reduction in EPS by 2025.

California – Kite, a major biopharmaceutical company based in California and a subsidiary of Gilead Sciences Inc., has announced its decision to acquire Philadelphia-based Interius BioTherapeutics for $350 million. The agreement will see Kite take over all outstanding shares of Interius BioTherapeutics, with the payment set to be made at the deal’s closing. This acquisition aims to bolster Kite’s capabilities in developing next-generation in vivo therapies.

Following the completion of the transaction, Interius’s team and operations are expected to merge into Kite’s research department. A center of excellence will be established in Philadelphia, dedicated to the development of in vivo therapies, which are aimed at generating chimeric antigen receptor (CAR) T-cells directly within patients’ bodies, a process that differs significantly from traditional methods.

Interius BioTherapeutics has created an innovative in vivo platform, enabling the direct insertion of DNA into a patient’s genome. Unlike conventional CAR T therapies, which necessitate a more complex procedure including cell harvesting, engineering, and reinfusion, Interius’s novel approach allows therapies to potentially be administered through a single intravenous infusion without the requirement for preconditioning chemotherapy.

The versatility of Interius’s platform allows for rapid adjustments across various medical conditions, which could significantly enhance patient access to necessary cell therapies, especially for those dealing with rapidly progressing diseases. The acquisition is designed to leverage both Interius’s technological advancements and Kite’s established expertise in cell therapy, with the goal of expediting the development of in vivo therapies efficiently.

Kite’s acquisition of Interius is also projected to impact Gilead’s earnings, with estimated reductions in both GAAP and non-GAAP earnings per share (EPS) of approximately $0.23-$0.25 anticipated by 2025. This financial element underscores the scale of the transaction and its projected influence on Gilead’s bottom line.

The closing of the acquisition remains dependent on the completion of customary conditions, including the expiration or termination of the waiting period outlined under the Hart-Scott-Rodino Antitrust Improvements Act. Financial advisory services for the acquisition are being provided by TD Cowen for Kite, while Evercore is advising Interius.

Kite has established itself as a leader in cell therapy, providing treatment to more patients with CAR T-cell therapies than any other organization. Meanwhile, Gilead Sciences, which operates globally in over 35 countries, has historically been associated with significant medical breakthroughs spanning more than three decades. Interius BioTherapeutics, on the other hand, is known for its engineering of targeted and programmable vectors designed for the precise delivery of genetic medicines, focusing on treatment for various complex diseases.

Key Terms

• Kite: A California-based biopharmaceutical company and a part of Gilead Sciences Inc.
• Interius BioTherapeutics: A Philadelphia-based company specializing in in vivo gene therapy platforms.
• CAR T-cells: A type of cancer treatment that modifies a patient’s T cells to attack cancer cells.
• In Vivo Therapy: Treatments administered directly inside the body, as opposed to outside or ex vivo.

Implications of the Acquisition

• Strengthens Kite’s capabilities in developing innovative therapies.
• Potentially reduces treatment timelines and enhances patient outcomes.
• Financial implications for Gilead Sciences’ earnings in the coming years.
• Establishes a new center of excellence for advanced therapy research in the Philadelphia region.

Outlook

The acquisition of Interius BioTherapeutics positions Kite to further solidify its leadership role in the biopharmaceutical market. The merger could lead to significant advancements in treatment methodologies for patients suffering from various diseases, marking a promising shift in therapeutic approaches.

FAQ

Deeper Dive: News & Info About This Topic

• Business Wire: Kite to Acquire Interius BioTherapeutics
• Reuters: Gilead Unit to Acquire Interius for $350 Million
• AI News: Gilead Sciences Kite to Acquire Interius for $350M
• Wikipedia: Gene Therapy
• Google Search: Kite Pharmaceuticals

Author: STAFF HERE HUNTINGTON BEACH

The Huntington Beach Staff Writer represents the experienced team at HEREHuntingtonBeach.com, your go-to source for actionable local news and information in Huntington Beach, Orange County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as the Huntington Beach Surf City USA Marathon, the U.S. Open of Surfing, Fourth of July celebrations at the Huntington Beach Pier, and community festivals at Huntington Beach Central Park. Our coverage extends to key organizations like the Huntington Beach Chamber of Commerce and Visit Huntington Beach, plus leading businesses in retail, hospitality, and outdoor recreation that drive the local economy. As part of the broader HERE network, including HEREAnaheim.com, HERECostaMesa.com, HERESantaAna.com, and HERELosAngeles.com, we provide comprehensive, credible insights into Southern California's dynamic landscape.